The GLP-1 Candy Store: When Prescription Medicine Starts Looking Like E-Commerce

How a powerful class of weight-loss drugs became a consumer product,and what gets lost when getting the prescription becomes easier than understanding the patient

You are scrolling through your phone late at night. An advertisement tells you losing weight no longer has to be so difficult. You click. A polished website asks your height and weight. There are some medical questions. Maybe you upload a photograph. You enter a credit card. A clinician somewhere reviews the information. Soon afterward, the prescription is approved. A box arrives.

There are obvious benefits to making healthcare easier to access, and telehealthMedical care delivered via phone or video. has solved real problems for millions of patients. But take a moment and think about how unusual this particular experience has become.

These are not vitamins. SemaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide are powerful prescription drugs that alter appetite and metabolism, can produce substantial changes in body weight, and may become long-term treatments. For appropriate patients, they can be extraordinary medicine. Yet the buying experience increasingly resembles something between a health subscription and e-commerce. The strange part is that we have become so accustomed to it that it barely feels strange anymore.

Nobody seriously believes obesity became biologically simple because semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. was invented. What changed is that medicine found a drug powerful enough to make some of that complexity easier to ignore. And in July 2026, researchers finally tested just how easy the path from I want a GLP-1 to your prescription has been approved can actually be.

Researchers Tried to Get GLP-1 Prescriptions From 49 Websites

A Yale-led research team published a secret-shopper study in JAMA. The researchers created a fictitious patient who met clinical eligibility criteria for GLP-1 treatment and attempted to obtain prescriptions through 49 websites selling these medications online.

Forty-five of the 49 sites—91.8%—issued a prescription. Thirty-four ultimately mailed medication to the researchers. That number gets your attention. The details are even more revealing. Every site used some form of questionnaire, but only 26 of the 49 asked about diet and physical activity. Twenty-seven asked about eating disorders. Only 18 requested patient-reported clinical values such as blood pressure, blood glucose, cholesterol, or triglycerides. Only 13 required a video visit. Three required a phone call. Among websites that prescribed, the median time to prescription was one day or less. Two compounded prescriptions were issued in five minutes or less. Thirty-four sites automatically charged the patient and shipped the medication after prescription approval without another confirmation. Three clinicians prescribed to the same fictitious patient through two or more websites. And of the 45 prescriptions issued, 39 were for compounded semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. or tirzepatide rather than branded medications.

Now, there is an important qualification. The researchers deliberately created a patient who qualified for GLP-1 treatment. This was not a study showing that 45 out of 49 companies recklessly prescribed medication to someone who should never have received it. It does not prove that 91.8% of these prescriptions were medically inappropriate. But that isn't really the disturbing part of the study. What it shows is how little medical friction can stand between wanting a serious prescription drug and receiving it.

The researchers themselves concluded that some direct-to-consumer platforms appeared to achieve increased access through impersonal care that favored rapid prescribing over comprehensive evaluation.

Read the study and a much larger question starts to emerge: when the patient arrives because an advertisement has already selected the medication, what exactly is the medical encounter being asked to decide?

Is the clinician starting with the patient and asking what treatment that patient needs? Or is the system starting with the treatment and asking whether there is any reason not to approve it? Those are very different models of medicine.

The Drug Can Work While the Medicine Around It Fails

The easiest way to think about unsafe prescribing is to imagine something dramatic: the wrong dose, a dangerous contraindication, a hospitalization. But there is another kind of harm that is much quieter and almost impossible to count. It is what never gets diagnosed. Maybe the patient is sleeping four or five hours a night and has significant untreated sleep apnea. Maybe depressionA prolonged low mood that interferes with life. worsened at roughly the same time the weight began climbing. Maybe there is binge eating nobody asked much about. Maybe a psychiatric or other medication contributed materially to the weight gain. Maybe metabolic disease, hormonal issues, alcohol use, chronic stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., loss of muscle, or several factors together are part of the story.

Then the GLP-1 works. The patient loses 25 pounds. Everybody is happy.

And that is exactly what makes this problem difficult to see. The drug can work while the medicine around it fails. Nobody complains that the sleep disorder was never diagnosed because the scale is moving in the right direction. Nobody notices that the patient is losing muscle along with fat unless somebody measures it. The medication gets renewed because, judged by its most visible endpoint, treatment is successful. But successful weight loss and comprehensive medical care are not the same thing.

This was the point of our earlier Fountain Health article, “Before GLP-1, Diagnose the Human.” Obesity medicine increasingly recognizes that weight sits at the intersection of metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., mental health, sleep, medications, eating behavior, physical function, environment, and other biological factors. A GLP-1 may absolutely belong in that treatment plan. The problem arises when qualifying for the drug becomes a substitute for understanding the patient.

But How Can This Possibly Be Legal?

This is usually the next question. If these are serious prescription drugs, how can a patient go from advertisement to questionnaire to medication so quickly?

The answer begins with a distinction most consumers understandably never think about: FDA approves the drug. FDA does not practice medicine.

The Food and Drug Administration evaluates whether a drug has sufficient evidence of safety and effectiveness to be marketed for particular indications. It regulates manufacturing, labeling, promotion, and other aspects of the drug itself. But FDA has long stated that it generally does not regulate the day-to-day practice of medicine. Once an approved drug reaches the market, decisions about how physicians treat individual patients are principally governed through state medical laws, licensing requirements, professional standards, and liability rules.

That arrangement is not some accidental GLP-1 loophole. It is a basic feature of American medicine, and there are good reasons for it. Nobody wants Washington writing a federal checklist for every clinical encounter. The unintended consequence is that FDA can establish that semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. or tirzepatide is an appropriate treatment for an indicated population without dictating exactly how much diagnostic work must happen before an individual clinician prescribes it.

There is no federal GLP-1 rule requiring every patient first to receive a sleep evaluation, PHQ-9A validated questionnaire used to screen for and measure depression severity., eating-disorder screen, body-composition test, endocrine assessment, metabolic panel, or 45-minute physician visit. Professional guidelines may recommend broader assessment. A state's standard of care still applies. Clinicians still have professional obligations. But those are not the same as an FDA-mandated pre-prescription protocol.

There is another practical difference: Wegovy and Zepbound are prescription drugs, but they are not federally scheduled controlled substances. Their current official drug labels list no DEA schedule. So the unusual restrictions Americans associate with remotely prescribing opioids, stimulants, or other controlled drugs are not what governs access to these medications. Suddenly the apparent mystery is less mysterious.

A drug can be powerful, prescription-only, potentially long-term, and still be comparatively easy to prescribe remotely. Whether the resulting encounter represents excellent medicine is a different question.

Then We Put the Prescription Drug Into the Advertising Machine

Now add another distinctly American feature. Prescription drugs can be advertised directly to consumers.

An advertisement cannot legally say anything it wants. Drug promotion is regulated, and false or misleading claims can trigger FDA enforcement. But there is an enormous difference between policing individual misleading claims and preventing an entire consumer culture from forming around a medication.

Nobody has to say:

Everybody should take Ozempic.

The message can be much subtler:

Weight loss can be easier. See if you qualify. Start today.
Clinically proven. No insurance needed. Delivered to your home.

Nothing about those ideas, standing alone, necessarily means the underlying treatment is inappropriate, but collectively, something important happens. The patient stops entering the medical system saying: I am gaining weight. Why? The patient enters saying: I want this drug. Can I have it? The diagnosis and the product have quietly changed places.

FDA itself now acknowledges the broader concern. In September 2025, the agency launched a major effort against misleading direct-to-consumer pharmaceutical advertising and warned that DTC promotion can increase demand even when a medication may not be clinically appropriate, while also distorting how patients perceive benefits and risks. FDA specifically pointed to digital advertising, social media, and influencer promotion as increasingly blurring the boundary between medical information and marketing.

In other words, regulators understand the psychology. The advertisement does not merely inform a patient that a treatment exists. It can create the patient who arrives requesting the treatment.

Compounding Poured Gasoline on the GLP-1 Marketplace

Then came the shortages. Demand for semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide exploded, branded drugs became difficult to obtain, and federal compounding law provided pathways under which pharmacies and outsourcing facilities could make compounded versions during shortage conditions.

Compounding has a legitimate and important role in American medicine. Sometimes an individual patient genuinely needs a medication in a strength or formulation that a commercial manufacturer does not supply, but the GLP-1 shortages created something much bigger.

Suddenly, a commercial pipeline could look like this: Advertising brings in the customer. An online platform conducts the intake. A remotely located clinician writes a prescription. A compounding pharmacy supplies the drug. The medication ships directly to the patient's home. Insurance may never enter the picture. For a cash-paying patient, enormous friction disappears.

The JAMA researchers found just how central compounded medicationsCustom prescriptions made by a pharmacy to fit individual needs. In clinical practice, they're tailored for dose, delivery method, or combined ingredi... had become to this market: 39 of the 45 prescriptions they obtained were for compounded semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. or tirzepatide, but the original shortage rationale has changed.

FDA determined the tirzepatide injection shortage was resolved in late 2024 and the semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. injection shortage in February 2025. In April 2026, the agency again reminded compounders that once commercially available approved drugs are no longer in shortage, federal law places important restrictions on routinely compounding products that are essentially copies of those drugs. Patient-specific compounding can remain permissible under particular circumstances, but it is not supposed to become an unlimited substitute supply chain for an available FDA-approved product.

This distinction is important, because compounded drugs are not FDA-approved drugs. That does not mean a compounded medicationCustom prescriptions made by a pharmacy to fit individual needs. In clinical practice, they're tailored for dose, delivery method, or combined ingredi... is automatically bad. It means FDA does not review each compounded drug for safety, effectiveness, and quality before it is marketed in the same way the agency reviews an approved branded or generic product.

And once the shortages ended, some companies found another rationale for continued compounding: personalization. Different doses. Added vitamins. Modified formulations. Patient-specific variations.

The JAMA researchers noticed this too. They described sellers asking questions related to “personalization” and offering supplements or altered formulations in what the authors characterized as individualization at scale after the GLP-1 shortages.

There is something almost philosophically strange about “individualization at scale.” True personalization is supposed to begin with an individual patient's medical need. Once millions of consumers are receiving slightly modified versions of the same commercially available drug through an industrialized sales funnel, regulators understandably start asking whether personalization is still the reason—or merely the legal architecture.

The Safety Questions Are Real

FDA has reported a number of concerns involving unapproved compounded semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide. Some have involved patients measuring incorrect doses from multidose vials. Some reports have involved clinicians miscalculating doses. FDA has also received reports involving patients being prescribed doses beyond the approved label or moving through dose escalation more rapidly than recommended.

The agency has warned about improper shipping temperatures, fraudulent products, and the use by some compounders of semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. salt forms that differ from the active ingredient used in FDA-approved products. As of May 31, 2026, FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Those numbers should not be sensationalized. An adverse-event report does not prove the compounded drug caused the event. Some reported reactions resemble known effects of FDA-approved GLP-1 drugs, and other factors can be involved.

There is also an important complication in the opposite direction: many state-licensed compounding pharmacies are not federally required to submit adverse-event reports to FDA, so the agency says events associated with compounded products are probably underreported.

The reasonable conclusion is neither “compounded GLP-1s are dangerous” nor “there is nothing to see here.” The reasonable conclusion is much simpler. These are serious medical products. They deserve serious medical oversight. Yet the visual and commercial language surrounding them can make the entire experience feel closer to ordering a skin-care subscription. That mismatch is the problem.

So Why Was Everybody So Quiet?

This is where the story becomes more interesting, because it is easy to tell yourself that regulators somehow did not notice. They noticed.

What changed is that the regulatory response arrived after the market had already become enormous. In February 2026, FDA announced plans to take action against non-FDA-approved GLP-1 products being mass-marketed as alternatives to approved medications. The agency specifically warned companies against presenting compounded products as generic versions of approved drugs, as the same thing as approved drugs, or as clinically proven equivalents when those claims were unsupported.

A month later, FDA announced warning letters to 30 telehealth companies over allegedly false or misleading claims involving compounded GLP-1 products. The agency said some marketing implied equivalence with FDA-approved products or obscured who was actually compounding the drugs. FDA has continued issuing individual warning letters to telehealthMedical care delivered via phone or video. companies involved in compounded semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide marketing.

The Federal Trade Commission has entered the picture too. In the NextMed case, the FTC alleged that the telehealthMedical care delivered via phone or video. company used deceptive pricing and weight-loss claims, fake testimonials, distorted consumer reviews, and problematic billing and cancellation practices while selling programs that provided access to GLP-1 prescriptions. A final FTC order approved in December 2025 imposed restrictions on those practices and required $150,000 expected to be used for consumer refunds. So no, regulators are not literally silent anymore.

The more uncomfortable question is why this model became culturally normal before the response became equally visible. GLP-1 advertising, subscription medicine, compounded supply, online intake, remote prescribing, and home delivery had already become familiar consumer experiences.

The regulators did not create the candy store. They arrived after it had customers.

Follow the Incentives

This does not require a conspiracy theory. The ordinary incentives are powerful enough. Imagine two businesses.

The first effectively says: Come to us for GLP-1. Its advertising attracts people who already want semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. or tirzepatide. The prospective patient becomes a paying customer when treatment is approved. Recurring treatment means recurring revenue.

The second says: Come to us because your weight or metabolic health has changed. We will figure out why and determine what treatment makes sense. That business may prescribe exactly the same GLP-1 medication, but the starting point is completely different.

For the first business, discovering that the patient does not need the advertised product can be commercially inconvenient. Maybe the patient needs an eating-disorder evaluation first. Maybe a sleep problem deserves attention. Maybe a medication is contributing. Maybe the patient does not currently need pharmacologic weight loss at all. For the second business, those are legitimate medical conclusions. No one says here that every telehealthMedical care delivered via phone or video. GLP-1 company practices bad medicine. Many clinicians working through telehealth platforms take their obligations seriously, and telemedicine can provide excellent care. Nor does it mean an office visit is automatically more thoughtful than an online encounter. Plenty of rushed medicine happens inside expensive buildings. The problem is structural.

When the business acquires the customer by advertising a particular prescription, the medical system begins the encounter with a conclusion already sitting on the table. And the faster the funnel becomes, the more valuable it is commercially. That deserves scrutiny.

A pharmacy's job is to dispense medication. A consumer company's job is to acquire and retain customers. A medical practice has a different obligation: figure out what the patient actually needs, even when the answer is inconvenient.

The Invisible Damage Is What Nobody Measures

Suppose a patient takes tirzepatide, loses 35 pounds, improves glucose levels, and feels fantastic. That is a good outcome.

Now suppose the same patient had severe sleep apnea that was never diagnosed, depressionA prolonged low mood that interferes with life. nobody explored, little resistance training, and substantial muscle loss during treatment. Did the GLP-1 fail? Of course not. Did the patient receive everything modern medicine could reasonably have offered? That is harder to answer.

This is why the consequences of prescription-first medicine will be difficult to capture in conventional safety statistics. The invisible damage is often not an adverse event. It is the question nobody asked. The diagnosis nobody pursued. The underlying condition nobody treated.

The patient who becomes dependent on a refill architecture because nobody built a broader treatment architecture around the medication.

Some patients may appropriately remain on GLP-1 therapy for many years. Obesity is a chronic disease, and long-term pharmacotherapy is not inherently a failure, but there is a profound difference between long-term medication as part of long-term medical care and long-term medication because medication became the entire care model. That distinction is going to matter more as these drugs become even more common.

What Fountain Health Does Differently

Fountain Health prescribes GLP-1 medications. So, this is not an anti-GLP-1 argument. In appropriate patients, semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide can be exceptional treatments, and a serious medical practice should not make an effective medication unnecessarily difficult to obtain. The difference is where the process starts.

Weight management sits inside our broader Mind-Body medical model that can look at metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., relevant laboratory findings, mental health, sleep, eating behavior, current medications, nutrition, body compositionThe balance of muscle, fat, and water in the body., stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., fitness, and hormonal or endocrine contributors where clinically indicated.

Not everybody needs every test. Not everybody needs to see five specialists. “Comprehensive” should not become another excuse for unnecessary diagnostics. The goal is quite simple:

The treatment should emerge from the assessment rather than the assessment being designed to approve the treatment.

For one patient, that assessment may make the argument for GLP-1 therapy stronger. For another, medication may be appropriate but should be combined with treatment of sleep apnea, depressionA prolonged low mood that interferes with life., binge eating, or another condition. For someone else, another problem may deserve attention first. And once medication begins, care should not collapse into a monthly transaction whose only questions are whether the scale went down and whether the next box shipped.

What is happening to metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health.? Nutrition? Strength? Muscle and body compositionThe balance of muscle, fat, and water in the body.? Sleep? Mental health? Physical function? Side effectsUnintended effects from treatment.? Long-term risk? That is medical management.

The Real GLP-1 Debate Is Not About Whether the Drugs Work

They work. That is why this conversation is necessary. If these drugs were mediocre, there would be no GLP-1 candy store. There would be no advertising arms race and no explosion of businesses trying to eliminate every possible inconvenience between the consumer and the prescription.

Their effectiveness created the market. Their effectiveness also creates the temptation to stop asking harder questions. Nobody suddenly discovered that obesity has one cause. Nobody proved sleep no longer matters, medications no longer matter, mental health no longer matters, metabolic disease no longer matters, or eating behavior no longer matters. We simply developed a treatment powerful enough to produce dramatic results despite all of that complexity. And that is both an extraordinary achievement and a medical temptation.

There is nothing wrong with removing pointless friction from healthcare. American medicine has more than enough bureaucracy already, but there is a point at which removing friction from treatment becomes removing medicine from treatment. The July 2026 JAMA study suggests that in parts of the online GLP-1 market, we should at least ask whether that line has been crossed. FDA's advertising crackdown, its warning letters to telehealthMedical care delivered via phone or video. companies, its actions around compounded GLP-1 products, and the FTC's enforcement activity suggest regulators are now asking versions of the same question.

The answer should not be to make legitimate GLP-1 treatment difficult. It should be to remember why prescription drugs require medical professionals in the first place.

Sometimes the correct answer after a serious evaluation will be semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation.. Sometimes it will be tirzepatide plus treatment of several other problems. Sometimes it will be something else. The important thing is that the answer comes from understanding the patient, not from the advertisement that brought the patient through the door.

Clinical and Regulatory References

Chetty AK, Chen AS, Ross JS, Ramachandran R. — Online Prescribing of GLP-1 Receptor Agonists. JAMA. 2026;336(5):428–431. Published online July 6, 2026.
Secret-shopper study examining GLP-1 prescribing through 49 online sellers, including clinician interaction, questionnaires, prescription timing, compounded products, and fulfillment.

U.S. Food and Drug Administration — FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss.
FDA discussion of compounded GLP-1 dosing errors, excessive dosing and titration, shipping and quality concerns, semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. salt forms, and reported adverse events.

U.S. Food and Drug Administration — FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.
FDA explanation of the resolved semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide shortages and current restrictions involving compounded products that are essentially copies of commercially available drugs.

U.S. Food and Drug Administration — FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. February 6, 2026.
FDA statement announcing intended enforcement against mass-marketed non-FDA-approved compounded GLP-1 products and misleading equivalence claims.

U.S. Food and Drug Administration — FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. March 3, 2026.
FDA enforcement involving allegedly false or misleading marketing of compounded semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide products.

U.S. Food and Drug Administration — Letter to Industry on Direct-to-Consumer Prescription Drug Advertising. September 9, 2025.
FDA warning regarding misleading DTC prescription-drug advertising, inappropriate demand, risk-benefit perception, digital advertising, and influencer promotion.

U.S. Food and Drug Administration — New Drug, Antibiotic, and Biologic Drug Product Regulations.
FDA's longstanding explanation of the distinction between regulating approved drugs and regulating the practice of medicine.

Federal Trade Commission — NextMed GLP-1 Weight-Loss Marketing Case.
FTC action involving alleged deceptive weight-loss claims, pricing practices, fake testimonials, manipulated reviews, billing, and cancellation practices. Final order approved December 2025.

DailyMed — Wegovy (semaglutide) and Zepbound (tirzepatide) Prescribing Information.
Current official drug labels; both list DEA Schedule as none.

Written by Fountain Health Clinical Editorial Team

Medically reviewed by Doreen Zarfati, MD

Updated: October 2026

Fountain Health is a multidisciplinary medical practice in New York City providing care across mental health, metabolic health, longevity, sleep, nutrition, fitness, and related areas of advanced medicine. This article is for educational purposes and does not replace individualized medical evaluation.